Problem
Healthcare professionals are often overwhelmed with data, making the interpretation challenging in clinical decision making.
Solution
cNeuro® from Combinostics gives healthcare professionals a comprehensive view of patient data which helps them to make an early diagnosis of neurodegenerative diseases.
While there are no effective treatments for neurodegenerative diseases like Alzheimer’s, early-stage diagnosis combined with symptomatic treatment and lifestyle intervention can make a drastic difference to quality of life in later years.
Products
cNeuro® is Combinostics’ cloud platform for quantitative assessment of brain images and for providing clinical decision support in neurological disorders.
cNeuro® has two product modules, cMRI and cDSI.
cNeuro® cMRI
Quantify volumes of 133 brain regions, vascular burden and in the EU, compute medial temporal lobe atrophy (MTA) score, global cortical atrophy (GCA) scale and Fazekas scale.
Compare measures to reference data.
Review results interactively in a web viewer using a standard web browser and obtain a report.
cNeuro® cDSI
Compare neuropsychology, MRI, CSF and genetics measured from your patient to data of previously diagnosed cases.
Quantify the patient’s similarity relative to etiology (AD, FTLD, VaD and cognitive normal) and progression (stable and progressive MCI).
Visualize data in an intuitive way with our patented disease state fingerprint (DSI) technology.
Meet us at RSNA
Combinostics will be attending the RSNA conference in Chicago December 1 – 6. You can find us in the AI Showcase, Level 1, North Hall, booth 10532B (see floorplan).
Combinostics raises €3.9M to support early Alzheimer’s diagnosis by healthcare professionals
Series A round lead investors NordicNinja and Industrifonden to support Combinostics as they scale to US and Asia HELSINKI, Finland (November 21st, 2019) Finnish health tech pioneer Combinostics has announced the closure of a...
Nihon Medi-Physics and Combinostics Enter into an Exclusive Agreement to Develop and Market Software to Support Diagnosing Dementia
Tokyo Japan and Tampere, Finland July 3, 2019, Nihon Medi-Physics Co., Ltd. (NMP) and Combinostics Oy (Combinostics) today announced the signing of an exclusive agreement to develop and market cloud-based dementia diagnosis support software (the Software) in Japan....